Sun Yat-sen University

This study tests whether giving targeted drugs before surgery can shrink tumors enough to remove them in people with stage III lung cancer that has rare gene mutations. About 120 adults who have not had treatment will receive a drug matched to their tumor's mutation, then surgery…

This phase 3 trial tests whether adding immunotherapy to standard treatment can improve outcomes for people with advanced nasopharyngeal cancer. About 802 participants will receive either standard chemoradiotherapy or a combination with immunotherapy and a chemotherapy pill. The …

This study tests whether a low dose of radiation, combined with an immunotherapy drug (pucotenlimab) and chemotherapy (CAPEOX), can shrink or eliminate locally advanced rectal cancer before surgery. About 50 adults with a specific type of rectal cancer (pMMR/MSS) will receive eit…

This study tests whether a special low-calorie diet that mimics fasting can make standard chemotherapy and immunotherapy work better for people with early or locally advanced triple-negative breast cancer. About 80 participants will receive the diet alongside their usual treatmen…

This study tests whether adding precise, high-dose radiation (SBRT) to standard drug therapy can help people with kidney cancer that has spread to up to 5 places live longer without the cancer growing. About 252 adults with this type of cancer will be randomly assigned to get eit…

This study tests whether adding a tumor-freezing procedure (cryoablation) and a low-dose chemotherapy drug (cyclophosphamide) to standard hormone therapy can better control metastatic prostate cancer. About 104 men with newly diagnosed, advanced prostate cancer will receive this …

This study is for people with non-small cell lung cancer that has spread to the brain (1 to 10 spots). Researchers want to see if using MRI-guided radiation without the usual extra safety margins can still be effective while lowering the risk of brain tissue damage. About 168 adu…

This study tests whether adding low-dose radiation to immunotherapy (toripalimab) and chemotherapy can help control recurrent or metastatic nasopharyngeal carcinoma. About 55 adults aged 18-65 with this type of cancer will receive the combination. The goal is to see if it delays …

This study tests a new drug (trastuzumab rezetecan) alone or with an immunotherapy (adebrelimab) for people with advanced or metastatic bladder cancer that has a specific protein called HER2. The goal is to see if these treatments can shrink tumors or slow cancer growth. About 96…

This study is testing whether a combination of two drugs (orelabrutinib and rituximab) followed by long-term orelabrutinib can shrink tumors or slow disease in people whose follicular lymphoma has come back or stopped responding to prior treatment. About 32 adults will receive th…

This study is for adults with a specific genetic form of advanced colorectal cancer (BRAF V600E) that has worsened after standard treatments. Researchers want to see if adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy and a targeted drug can …

This study tests whether adding two liver-directed treatments (chemoembolization and artery infusion) to standard immunotherapy can shrink tumors more effectively in people with advanced liver cancer that cannot be removed by surgery. About 55 adults with good liver function and …

This study tests a combination of two drugs, eribulin and anlotinib, for people with HER2-negative breast cancer that has spread or come back. Participants have already tried other treatments like antibody-drug conjugates, but their cancer continued to grow. The goal is to see if…

This study tests whether adding the drug selinexor to standard chemotherapy (R-CHOP) can improve outcomes for people with a specific, hard-to-treat type of lymphoma (TP53-mutated DLBCL). About 42 adults who have not received prior treatment will get the combination, followed by m…

This study is for people with advanced triple-negative breast cancer that has not been treated with chemotherapy yet. It tests different ways of combining radiation therapy with immunotherapy to see which pattern works best to stop the cancer from growing. The goal is to control …

This study tests a new treatment sequence for people with high-risk nasopharyngeal cancer. It compares immunotherapy combined with chemotherapy and radiation followed by maintenance immunotherapy versus standard maintenance with capecitabine. The goal is to see which approach bet…

This study tests whether giving two drugs (pucotenlimab and vorolanib) before surgery can shrink kidney tumors enough to allow partial kidney removal instead of full removal. It involves 21 adults with high-risk clear cell renal cancer who need surgery. The goal is to see if this…

This early-phase study tests a new drug called WTX212A, given alone or with radiation, in 12 people with advanced solid tumors. The goal is to see if it shrinks tumors and is safe. It is for patients aged 18-75 with confirmed advanced cancer.

This study tests whether combining two drugs—zanubrutinib (a pill) and rituximab (an infusion)—can shrink or control MALT lymphoma, a slow-growing cancer of the lymph nodes. About 42 adults with advanced or newly relapsed disease will receive the combo as their first systemic tre…

This study tests whether giving a combination of drugs (IBI308, bevacizumab, pemetrexed, and carboplatin) before surgery can shrink stage III non-small cell lung cancer enough to allow surgical removal. The trial enrolls 36 adults whose cancer cannot currently be operated on. The…

This study tests whether a blood test that detects tiny bits of cancer DNA can help doctors decide who needs extra immunotherapy after lung cancer surgery. About 80 people with stage IB-IIIA non-small-cell lung cancer will receive toripalimab only if their blood test shows signs …

This study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely receive less radiation afterward. About 50 participants will be followed for two years to see if the cancer stays away and if their quali…

This study tests whether giving radiation only when needed (salvage) is as effective as giving it right away after immunotherapy and chemotherapy in people with nasopharyngeal cancer that has spread. About 260 adults aged 18-70 with untreated, metastatic disease will be randomly …

This study tests whether adding two targeted drugs (cetuximab and envafolimab) to a strong chemotherapy cocktail works better than the standard treatment for people with a specific type of advanced colorectal cancer that has spread to the left side of the body. About 198 adults w…

This study tests whether adding low-dose radiation and an immunotherapy drug (cadonilimab) to standard chemotherapy before chemoradiation can help people with advanced nasopharyngeal cancer live longer without the cancer coming back. About 380 adults aged 18-70 with newly diagnos…

This study tests whether removing extra safety margins during precise, adaptive radiation therapy can lower the risk of lung side effects while still controlling tumors. It involves 130 adults with early-stage non-small cell lung cancer or a few lung tumors that have spread from …

This study tests whether adding a probiotic (Biolosion) to standard chemotherapy before surgery can help more women with early-stage triple-negative breast cancer achieve a complete response (no cancer found at surgery). About 192 women will be randomly assigned to receive either…

This study tests an experimental drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery. Participants receive the drug every 3 weeks. The main goal is to see if the drug can stop tumor growth for at least 12 weeks, while also c…

This study tests a new way of giving chemotherapy called adaptive therapy for people with advanced breast cancer that has gotten worse after standard treatments. The goal is to see if this approach can delay the cancer from growing again. About 192 adults will take part in this p…

This study tests whether giving chemotherapy directly into the liver plus an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from returning in high-risk patients. About 39 adults with liver cancer that is be…

This study tests a combination of three drugs (chidamide, sintilimab, and bevacizumab) in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has worsened after standard first-line therapy. The goal is to see if this treatment can shrink tumors or slow disease pr…

This study tests whether giving the immunotherapy drug adebrelimab directly into the liver artery works better than standard IV infusion, when combined with chemotherapy and another targeted drug (bevacizumab). About 76 adults with advanced liver cancer that has spread will be ra…

This study tests two ways to treat lung cancer that has spread to the brain. One group gets focused radiation plus a drug called bevacizumab. The other gets whole-brain radiation that tries to protect the memory center. The goal is to see which approach better controls tumors and…

This study compares a reduced dose of radiation to the standard dose for low-risk areas in people with nasopharyngeal cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects and improving quality of life. About 700 adults …

This phase 3 trial tests whether adding two drugs—toripalimab (an immunotherapy) and capecitabine (a chemotherapy pill)—after standard chemoradiation can help prevent esophageal cancer from coming back. About 242 adults with advanced esophageal cancer that hasn't spread after ini…

This early-phase study tests a new treatment called IX001 TCR-T for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. The…

This study tests a drug called toripalimab, which helps the immune system fight cancer. It is for people with advanced solid tumors that have specific gene changes (POLE or POLD1 mutations) but not high microsatellite instability. About 35 adults who have not responded to standar…

This study tests whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiation, can help people with advanced nasopharyngeal cancer live longer without the disease getting worse. About 243 adults aged 18-7…

This study tests two new drug combinations for people with peripheral T-cell lymphoma (a rare blood cancer) that has returned or not improved after standard treatment. About 101 participants will receive either golidocitinib plus mitoxantrone liposome or golidocitinib plus chidam…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) before surgery can shrink kidney tumors enough to allow partial kidney removal in patients who otherwise would need full kidney removal. Ab…

This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) helps shrink tumors more effectively in people with locally advanced rectal cancer. About 556 adults aged 18-75 will be randomly assigned to receive either the drug combo or chem…

This study tests whether early, specialized heart monitoring and care can help people with advanced lung cancer live longer and have fewer heart-related side effects while receiving standard cancer treatments like radiation, chemotherapy, and immunotherapy. About 524 adults with …

This study is testing a new way to figure out where a cancer started when doctors can't find the original tumor. Researchers will use a computer model to analyze DNA patterns from 120 cancer patients. The goal is to help guide more precise treatment for these hard-to-diagnose can…

This study tests whether inhaling a drug called penehyclidine before surgery can prevent breathing complications in children aged 3 to 7 who are at higher risk. The trial involves 204 kids undergoing minor eye surgery with sevoflurane anesthesia. Half will receive the drug, half …

This study tests whether adding Houyanqing Oral Liquid to standard care can prevent severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. About 244 adults aged 18–75 who need radiation will be randomly assigned to receive either the herbal liquid pl…

This study tests whether Xinlikang capsules can reduce severe tiredness and help the immune system recover in people with diffuse large B-cell lymphoma who finished chemotherapy and are in remission. About 80 adults will receive either the capsule or a placebo for a set time. The…

This study looks at whether a blood test can help doctors monitor neuroblastoma, a type of childhood cancer. Researchers will collect blood samples from 200 patients over time to check for tiny bits of tumor DNA. The goal is to see if these tests can show how well treatment is wo…

This study aims to discover new chemicals in the body (metabolites) that may influence heart valve disease and its progression. Researchers will follow 4,000 adults diagnosed with any type of heart valve disease, tracking their health and testing tissue samples. The goal is to fi…

This study reviews medical records of 446 people with hepatitis B-related acute-on-chronic liver failure who received stem cell therapy. Researchers want to find out why some patients improve while others do not. The goal is to identify factors that affect treatment success, so f…

This study follows 2000 adults with moderate or severe mitral regurgitation (a leaky heart valve) to identify factors that raise the risk of death or heart failure. Researchers will use this information to create a risk model that helps doctors decide on the best treatment. Parti…